Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Pujol, Jean Louis; Pas, Tommaso De; Rittmeyer, Achim; Vallières, Eric; Kubisa, Bartosz; Levchenko, Evgeny; Wiesemann, Sebastian; Masters, Gregory A.; Shen, K. Robert; Tjulandin, Sergei; Hofmann, Hans‐Stefan; Vanhoutte, Nicolas; Salaun, Bruno; Debois, Muriel; Jarnjak, Silvija; Alves, Pedro Miguel De Sousa; Louahed, Jamila; Brichard, Vincent G.; Lehmann, Frédéric

doi:10.1016/j.jtho.2016.08.120

Cited by 73 publications

(86 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, PRAME is critical in the immunotherapy response and may be an attractive target for human cancer immunotherapy. Indeed, several clinical trials of PRAME immunotherapies have shown their safety and potent immune responses in melanoma, lung cancer and other advanced solid tumours . Antigen delivery and target specificity might affect the efficacy of PRAME immunotherapy.…”

Section: Conclusion and Perspectivementioning

confidence: 99%

“…67 At the same time, it has been shown that the PRAME immunotherapeutic dose of 500 µg is a safe and clinically acceptable dose. 67 Similarly, PRAME-derived peptides trigger frequent specific T-cell responses in patients with lung cancer and are an appropriate candidate for targeted immunotherapy. 68 Moreover, in the adjuvant setting, the most relevant and promising vaccine directly targeting PRAME could be a potential therapeutic approach for NSCLC patients.…”

Section: Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Zou

Wang

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.

show abstract

Section: Conclusion and Perspectivementioning

confidence: 99%

Section: Lung Cancermentioning

confidence: 99%

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Zou

Wang

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…Раково-тестикулярный человеческий антиген PRAME интенсивно исследуется в качестве компонента противоопухолевых вакцин как в виде рекомбинантного белка [18,19], где у пациентов после иммунизации был получен стойкий специфический гуморальный ответ, так и в виде синтетических пептидов, распознаваемых иммунной системой человека [20].…”

Section: развитие гуморального ответаunclassified

Recombinant human PRAME immunization reducesPRAME-expressing tumor growth in mice

Финашутина

Лыжко

Kasatkina

et al. 2018

Rossijskij bioterapevtičeskij žurnal

View full text Add to dashboard Cite

Intrоduction.Human antigen PRAME is preferentially expressed in a number of different tumor types and may be a potent target for anti-tumor immunotherapy.Purpose.To study anti-tumor action of immunogenic mix recombinant PRAME protein and adjuvant in mice with innate immunity.Materials and methods.C57BL/6 female mice were used for immunization with purified human recombinant protein PRAME. Human PRAME gene coding sequence was cloned in mammalian expressing vector pCEP4 and resulting plasmid was introduced in mouse melanoma B16F10 cells by transfection followed by RQ-PCR, Western blot and flow-cytometry analysis. Then stably PRAME-transfected melanoma cells were injected in mice.Results.The mouse melanoma B16F10 cells stably expressing human PRAME protein were obtained. We demonstrate the 10-fold decreased tumor volume in mice with melanoma B16F10 expressing human PRAME after preventive immunization series with recombinant PRAME protein. The tumor volume reducing was correlated with high titer (6.14 × 10 5) of anti-PRAME antibodies in mice sera.Conclusion.These data indicate that recombinant protein PRAME is immunogenic and may be a potent antigen for immunotherapuetics studies.

show abstract

“…Для поддержки CD8позитивных клеток авторы предложили сочетать PD1блокаду и вакцинирование. II фаза клинического исследования была прервана в связи с тем, что параллельно идущее исследование вакцины против MAGE-A3 не дало результатов, превосходящих плацебо [55].…”

Section: вакцинирование пептидами и белком Prameunclassified

Theory and Practice of Immunotherapy Directed against the PRAME Antigen

Misyurin¹

2018

Клиническая онкогематология

View full text Add to dashboard Cite

The preferentially expressed antigen of melanoma (PRAME) is a signifi cant target for monoclonal antibodies and an oncospecifi c marker known for its activity on all the tumor cell diff erentiation stages and its eliciting of a spontaneous T-cell response. Since PRAME protein is active in approximately every second patient with solid tumors and oncohematological diseases, anti-PRAME immunotherapy is very promising. In current review the mechanism of spontaneous immune response against PRAME is discussed as well as the role of this antigen in immunosurveillance. The review deals with the PRAME-specifi c T-cell genesis and risk assessment of immunotherapy directed against PRAME-positive cells. The risks and benefi ts of various immunotherapy approaches including the use of dendritic cell vaccines, PRAME vaccination, development of specifi c T-cells, and development of specifi c monoclonal antibodies were analysed. Possible causes of treatment failure are analysed, and methods of overcoming them are suggested. The literature search in the Pubmed, Scopus, and eLibrary databases, with the use of "PRAME" as a keyword was performed. Only publications related to various aspects of immunotherapy and anti-PRAME-specifi c agents were included in the review.

show abstract

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Cited by 73 publications

References 48 publications

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Recombinant human PRAME immunization reducesPRAME-expressing tumor growth in mice

Theory and Practice of Immunotherapy Directed against the PRAME Antigen

Contact Info

Product

Resources

About